Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You? (2026 India Guide)
Both drugs work. Tirzepatide averages 20–22% weight loss versus around 15% for semaglutide — and costs several times more. After the March 2026 generic launch, the price gap widened. Here's how doctors in India decide.
ALTRcare Medical Team
Clinical Editorial
The two most prescribed GLP-1 medications in India are semaglutide (the molecule in Ozempic, Wegovy, and now 40+ generics) and tirzepatide (the molecule in Mounjaro). Both are effective. They work differently, cost very differently, and suit different patients.
Semaglutide: the proven standard
Semaglutide has the longer track record and the larger body of clinical data. It's a GLP-1 receptor agonist — it slows gastric emptying, increases satiety, and reduces appetite.
- Average weight loss: around 15% of body weight over 6–12 months
- Cost in India (2026): since the patent expired on 20 March 2026, generic semaglutide starts from ~₹1,290/month. Branded Ozempic runs ₹5,660/month at the starter dose, rising to ₹8,000–16,000 at maintenance doses.
- Mechanism: single-action (GLP-1 only)
- Best for: first-time GLP-1 users, BMI 27–32, and anyone for whom long-term affordability matters
Tirzepatide: the stronger option
Tirzepatide is newer and works on two receptors instead of one — GLP-1 and GIP. That dual mechanism produces stronger results.
- Average weight loss: 20–22% of body weight over 6–12 months
- Cost in India (2026): Mounjaro (and Cipla's co-marketed Yurpeak) runs roughly ₹14,000–19,000/month depending on dose.
- Mechanism: dual-action (GLP-1 + GIP)
- Best for: BMI 30+, higher waist circumference, or patients who've plateaued on semaglutide
Why the price gap widened in 2026
Tirzepatide is still on-patent in India, so there are no generics yet. Semaglutide went generic in March 2026. That's why semaglutide can now cost a fraction of tirzepatide for similar — if slightly lower — results.
How your doctor decides
- Your BMI: higher BMI tends to justify the stronger molecule
- Waist circumference: above 90 cm (men) or 80 cm (women) — the India-specific thresholds — leans toward tirzepatide
- Budget over time: semaglutide is now dramatically more affordable for long-term treatment, which matters because GLP-1s only work while you take them
- Health profile: insulin resistance or pre-diabetes may favour the dual-action drug
Which one is right for you?
Take the 2-minute assessment. A doctor reviews your profile and recommends the right molecule and dose.
The bottom line
Both medications are safe and effective when prescribed and monitored by a doctor. Most patients start on semaglutide, then switch to tirzepatide after 3–6 months only if results plateau. Neither is right for everyone, both require baseline bloodwork, and both need careful dose titration. Your ALTRcare doctor will recommend the right option based on your bloodwork and goals.
Key takeaways
- Semaglutide: ~15% weight loss, now from ₹1,290/month generic — the sensible starting point for most.
- Tirzepatide: 20–22% weight loss, ~₹14,000–19,000/month, still on-patent (no generics yet).
- Most patients start on semaglutide and only escalate to tirzepatide if results stall.
- Both need a prescription, baseline bloodwork, and supervised titration.
Still deciding?
Message our care team and a doctor will help you weigh results, cost, and what fits your goals.
Frequently asked questions
Is tirzepatide better than semaglutide for weight loss?
Tirzepatide averages 20–22% body-weight loss versus around 15% for semaglutide, so it's stronger on average. But it costs several times more and is usually reserved for higher BMI or plateaus.
Why is semaglutide so much cheaper than tirzepatide in India now?
Semaglutide's India patent expired on 20 March 2026, triggering 40+ generics from ₹1,290/month. Tirzepatide is still on-patent, so it has no generics and remains ₹14,000–19,000/month.
Which GLP-1 should I start with?
Most patients start on semaglutide for cost and tolerability, then consider switching to tirzepatide only if results plateau. A doctor decides based on BMI, waist size, and health profile.
Ready to take the next step?
Take the free 2-minute eligibility assessment. A doctor reviews it before anything is prescribed — no obligation.
This article is for general educational purposes and is not a substitute for personalised medical advice. GLP-1 medications are prescription-only and not suitable for everyone. Always consult a qualified doctor before starting, changing, or stopping any treatment.
